SALT LAKE CITY—Mirza Mansoor Raza, director at Sera Prognostics Inc. (NASDAQ: ), recently sold 100 shares of the company’s Class A common stock. The shares were sold at $7.69 each, for a total transaction value of $769. The transaction comes after SERA shares rose nearly 43% over the past six months, according to data InvestingPro data.
This transaction was completed on January 6, 2025, as part of an authorized “sale to cover” arrangement to satisfy withholding tax obligations related to the acquisition of restricted stock units. As a result, the sale does not constitute a discretionary decision by Mr. Raza. Following this transaction, Mr. Raza holds 6,536 shares directly in the company, retaining his stake in the $265 million market capitalization company.
Sera Prognostics, based in Salt Lake City, specializes in medical laboratory services. InvestingPro analysis shows that the company maintains strong liquidity with a current ratio of 2.11, although it currently trades above its fair value. Access 8 additional InvestingPro tips and comprehensive financial analysis via the Pro Research Report, available with an InvestingPro subscription.
In other recent news, Sera Prognostics released its fiscal 2024 third quarter financials, reporting a decrease in net income from $42,000 to $29,000. The company’s operating expenses increased by 8% to $8.9 million, and the net loss increased by 10% to $7.9 million. Despite these financial challenges, Sera Prognostics is focused on promoting the adoption of its PreTRM test and expects to publish the results of the PRIME study. This study is expected to play a significant role in influencing clinical guidelines and payer support. The company also reported a 227% increase in website traffic due to increased accessibility and educational campaigns. Despite the decline in revenue, Sera Prognostics maintains a strong cash reserve of $74.3 million, projecting its sustainability through 2027. These are just some of the recent events related to Sera Prognostics.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
